Serious Fraud Office Investigation

GlaxoSmithKline plc (LSE/NYSE: GSK) has today been informed by the UK's Serious Fraud Office (SFO) that it has opened a formal criminal investigation into the Group's commercial practices.

GSK is committed to operating its business to the highest ethical standards and will continue to cooperate fully with the SFO.

 

V A Whyte

Company Secretary

27 May 2014

 

GSK – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.GSK enquiries:

 

UK Media enquiries: 

David Mawdsley +44 (0) 20 8047 5502 (London)

Simon Steel +44 (0) 20 8047 5502 (London)

US Media enquiries:

Stephen Rea +1 215 751 4394 (Philadelphia)

Analyst/Investor enquiries:

Ziba Shamsi +44 (0) 20 8047 5543 (London)

Kirsty Collins (SRI & CG) +44 (0) 20 8047 5534 (London)

Tom Curry + 1 215 751 5419 (Philadelphia)

Gary Davies +44 (0) 20 8047 5503 (London)

James Dodwell +44 (0) 20 8047 2406 (London)

Jeff McLaughlin +1 215 751 7002 (Philadelphia)

Lucy Singah +44 (0) 20 8047 2248 (London)